---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-039135"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:16:30.158572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics reports FY2022 net loss of $3.6M; cash $6.7M; pipeline updates

## Summary
- Net loss $3.6M ($1.63/share) vs $3.7M ($3.29/share) in 2021; R&D $2.7M, G&A $5.3M.
- Cash $6.7M at Dec 31, 2022, up from $3.8M; raised $12M in Oct 2022 offering and $3.25M in Jan 2023.
- In-licensed AJ201 for SBMA (Kennedy's Disease) in Phase 1b/2a; FDA granted Orphan Drug Designation.
- IV Tramadol: Type C meeting with FDA in March 2023; update expected in April 2023.
- Completed acquisition of Baergic Bio in Nov 2022; appointed Alexandra MacLean to board.

## SEC filing metadata
- accession: 0001104659-23-039135
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/0001104659-23-039135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/tm2310303d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-039135
- JSON: https://secwatch.observer/filing/0001104659-23-039135.json
- Plain text: https://secwatch.observer/filing/0001104659-23-039135.txt

## Key facts
- Earnings Releases
  AVENUE THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: net income Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share, EPS $1.63 per share.
  - Period: the full year ended December 31, 2022
  - Net income: Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share
  - EPS: $1.63 per share
  - Result: reported results
  source text: Avenue Therapeutics, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/0001104659-23-039135-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.